Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma, Myeloid 1Sarcoma 1Rhabdoid Tumor 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Central Nervous System Neoplasms 1Blast Crisis 1

Interventions

Doxorubicin 6Radiotherapy 5selinexor 4pazopanib 3Sirolimus 3Ifosfamide 3AZD 6244 3pembrolizumab 2fludarabine phosphate 2Radiation Dose Hypofractionation 2Nivolumab 2Etoposide 2thymoglobulin 1temsirolimus 1tazemetostat 1sotigalimab 1ribociclib 1pexidartinib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1ixazomib 1fludarabine 1decitabine and cedazuridine drug combination 1X-Rays 1Thiotepa 1Tacrolimus 1Surgical Procedures, Operative 1Sunitinib 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neurofibrosarcoma × Razoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡